Long-term outcome from the SCALOP trial: a multi-centre randomized phase II trial of gemcitabine or capecitabine-based chemoradiation (CRT) for loc...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter C. Hurt
Citation Annals of Oncology (2016) 27 (2): 118-128. 10.1093/annonc/mdw198
Authors C. Hurt1, J. Bridgewater2, S. Falk3, S. Cummins4, H. Wasan5, T. Crosby6, G. Radhakrishna7, C. Jephcott8, R. Roy9, A. McDonald10, R. Ray11, G. Joseph6, J. Staffurth6, R. Abrams12, G. Griffiths13, T. Maughan14, S. Mukherjee15
  • 1Wales Cancer Trials Unit, Cardiff University, Cardiff, United Kingdom, /
  • 2University College London Cancer Institute, London, United Kingdom, /
  • 3University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom, /
  • 4St Luke's Cancer Centre, Royal Surrey County Hospital, Guildford, United Kingdom, /
  • 5Hammersmith Hospital, Imperial College NHS Trust, London, United Kingdom, /
  • 6Velindre NHS Trust, Cardiff, United Kingdom, /
  • 7St James' Institute of Oncology, Leeds, United Kingdom, /
  • 8Oncology Centre, Addenbrooke's Hospital, Cambridge, United Kingdom, /
  • 9Queen's Centre of Oncology & Haematology, Hull, United Kingdom, /
  • 10Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom, /
  • 11Wales Cancer Trials Unit, Cardiff, United Kingdom, /
  • 12Dept. of Radiation Oncology, RUMC, Chicago, Illinois, USA, /
  • 13Southampton Clinical Trials Unit, Southampton, United Kingdom, /
  • 14Gray Institute of Radiation Oncology and Biology, Oxford, United Kingdom, /
  • 15University of Oxford, Oxford, United Kingdom, /

Abstract

The SCALOP trial tested the safety and efficacy of gemcitabine (Gem) versus capecitabine (Cap) based CRT following induction chemotherapy and showed that GemRT was associated with greater toxicity and worse survival. Here we present the long-term outcomes.